Valneva SE (NASDAQ:VALN - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $8.33, but opened at $7.90. Valneva shares last traded at $7.71, with a volume of 84,288 shares changing hands.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Valneva in a research note on Friday, January 31st.
Get Our Latest Stock Analysis on VALN
Valneva Price Performance
The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock's 50-day moving average is $4.92 and its 200 day moving average is $5.64. The stock has a market capitalization of $542.01 million, a PE ratio of -51.31 and a beta of 1.98.
Institutional Trading of Valneva
A number of large investors have recently made changes to their positions in the company. ABC Arbitrage SA acquired a new stake in shares of Valneva in the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC boosted its position in shares of Valneva by 33.7% in the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock valued at $717,000 after purchasing an additional 29,748 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares during the period. 11.39% of the stock is owned by institutional investors and hedge funds.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Articles
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
